Press releases
Curium completes the acquisition of Monrol as part of its plan to significantly expand Lutetium-177 capacity and PET footprint
28th March 2025
Latest news, Events and Press Releases
Find all of our recent press releases, stay updated with the latest news and be informed about upcoming events where Curium will be attending.
Please direct any media inquiries to communications@curiumpharma.com
Press releases
Press releases
Curium Expands European Supply of Iodine-131 Diagnostic Capsules with New Partnership Agreement with Izotop
30th January 2025
Press releases
Curium Further Expands European Availability of Pylclari® – an Innovative 18F-PSMA PET Radiopharmaceutical Indicated in Patients With Prostate Cancer
28th January 2025
Press releases
Curium Completes Enrollment Early of Phase 3 SOLAR-RECUR Prostate Cancer Trial
19th November 2024
Press releases
Curium Announces ECLIPSE Trial Has Met Primary Endpoint, Demonstrating a Statistically Significant and Clinically Meaningful Benefit for Patients With PSMA-Positive Metastatic Castration Resistant Prostate Cancer
13th November 2024
Press releases
Curium Announces Strategic Partnership with PeptiDream for Prostate Cancer Theranostics in Japan
1st October 2024
Press releases
Curium announces the official opening of its new Netherlands facility for the production of Lutetium-177 – a game changer therapy isotope for cancer patients worldwide
24th September 2024
Press releases
Curium Announces Pylclari® – an Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer – is now available in Spain
10th September 2024
Press releases
Curium Submits New Drug Application for Lutetium Lu 177 Dotatate Injection
9th July 2024
Press releases
Curium Continues to Make Strong Progress in European roll-out of Pylclari® – ¹⁸F-PSMA PET Diagnostics of Patients With Prostate Cancer
17th June 2024
Press releases
Curium adds the Institut Laue–Langevin reactor to global irradiation portfolio to ensure continuous supply of Lutetium-177 benefit more than 100,000 cancer patients over the next 5 years
5th June 2024
Press releases
Curium Announces First Commercial Doses in France of Pylclari® – an Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer
30th May 2024